Drug Trial Radar · NCT00401596
A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)
Last checked: Nov 20, 2026Latest source record: Mar 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,899
Actual
Start
Jul 2000
Primary completion
Not stated
Study completion Jul 2002
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, open label, randomized, controlled, safety trial in subjects aged 6-75 years with a diagnosis of moderate to severe, persistent asthma. A total of 1899 subjects were randomized (2:1) to either the active treatment group or the control group. Upon successful completion of the screening period (\~2 weeks), each subject entered the 24 week study.
Conditions
- Asthma
Interventions
Xolair (omalizumab)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of all serious adverse events.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.